Skip to main content
Erschienen in: Cancer and Metastasis Reviews 4/2008

01.12.2008 | NON-THEMATIC REVIEW

Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents

verfasst von: Nicolas Magné, Cyrus Chargari, Eric Deutsch, Pierre Castadot, Mitra Ghalibafian, Jean Bourhis, Christine Haie-Meder

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Although conventional multimodality approaches allowed improvement in the prognosis of patients with cervix cancer, several tumors do not respond similarly to standard approaches. Recent advances in basic research and genomics have improved our understanding of the biologic basis of the tumor development and progression. Tumor profiling allows for more selective therapeutic strategies leading to the identification of biomarkers or indicators of treatment response and to increased clinical efficacy through development of targeted therapies. Several markers have been identified, that are involved in cellular proliferation, interaction with angiogenesis, extracellular matrice adhesion/invasion, apoptosis, cell cycle pathways and DNA repair mechanisms. In this report, molecular profiling of uterine cervix carcinoma were reviewed with a special focus on rationally designed target-based anticancer agents, in order to clarify and to summary the present state of art in these particular promising area in cervix cancer management.
Literatur
1.
Zurück zum Zitat Eifel, P. J. (2005). Chemoradiotherapy for cervical cancer: what next? Journal of Clinical Oncology, 23, 8277–8279.PubMed Eifel, P. J. (2005). Chemoradiotherapy for cervical cancer: what next? Journal of Clinical Oncology, 23, 8277–8279.PubMed
2.
Zurück zum Zitat Gray, H. J. (2008). Primary management of early stage cervical cancer (IA1-IB) and appropriate selection of adjuvant therapy. Journal of the National Comprehensive Cancer Network, 6, 47–52.PubMed Gray, H. J. (2008). Primary management of early stage cervical cancer (IA1-IB) and appropriate selection of adjuvant therapy. Journal of the National Comprehensive Cancer Network, 6, 47–52.PubMed
3.
Zurück zum Zitat Moore, D. H. (2008). Chemotherapy for advanced, recurrent, and metastatic cervical cancer. Journal of the National Comprehensive Cancer Network, 6, 53–57.PubMed Moore, D. H. (2008). Chemotherapy for advanced, recurrent, and metastatic cervical cancer. Journal of the National Comprehensive Cancer Network, 6, 53–57.PubMed
4.
Zurück zum Zitat Waggoner, S. E. (2003). Cervical cancer. Lancet, 361, 2217–2225.PubMed Waggoner, S. E. (2003). Cervical cancer. Lancet, 361, 2217–2225.PubMed
5.
Zurück zum Zitat Pötter, R., et al. (2006). Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiotherapy Oncology, 78, 67–77. Pötter, R., et al. (2006). Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiotherapy Oncology, 78, 67–77.
6.
Zurück zum Zitat Lindegaard, J.C., et al. (2008). MRI-Guided 3D Optimization Significantly Improves DVH Parameters of Pulsed-Dose-Rate Brachytherapy in Locally Advanced Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 71, 756–764. Lindegaard, J.C., et al. (2008). MRI-Guided 3D Optimization Significantly Improves DVH Parameters of Pulsed-Dose-Rate Brachytherapy in Locally Advanced Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 71, 756–764.
7.
Zurück zum Zitat Schlessinger, J. (2000). Cell signaling by receptor tyrosine kinases. Cell, 103, 211–225.PubMed Schlessinger, J. (2000). Cell signaling by receptor tyrosine kinases. Cell, 103, 211–225.PubMed
8.
Zurück zum Zitat Bonner, J. A., et al. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New England Journal of Medicine, 354(6), 567–578.PubMed Bonner, J. A., et al. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New England Journal of Medicine, 354(6), 567–578.PubMed
9.
Zurück zum Zitat Cerciello, F., et al. (2007). Is EGFR a moving target during radiotherapy of carcinoma of the uterine cervix? Gynecologic Oncology, 106(2), 394–399.PubMed Cerciello, F., et al. (2007). Is EGFR a moving target during radiotherapy of carcinoma of the uterine cervix? Gynecologic Oncology, 106(2), 394–399.PubMed
10.
Zurück zum Zitat Huang, S. M., Bock, J. M., & Harari, P. M. (1999). Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Research, 59, 1935–1940.PubMed Huang, S. M., Bock, J. M., & Harari, P. M. (1999). Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Research, 59, 1935–1940.PubMed
11.
Zurück zum Zitat Kersemaekers, A. M., et al. (1999). Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clinical Cancer Research, 5(3), 577–586.PubMed Kersemaekers, A. M., et al. (1999). Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clinical Cancer Research, 5(3), 577–586.PubMed
12.
Zurück zum Zitat Pillai, M. R., Jayaprakash, P. G., & Nair, M. K. (1998). Tumor-proliferative fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix. Journal of Cancer Research and Clinical Oncology, 124, 456–461.PubMed Pillai, M. R., Jayaprakash, P. G., & Nair, M. K. (1998). Tumor-proliferative fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix. Journal of Cancer Research and Clinical Oncology, 124, 456–461.PubMed
13.
Zurück zum Zitat Fuchs, I., et al. (2007). The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Research, 27(2), 959–963.PubMed Fuchs, I., et al. (2007). The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Research, 27(2), 959–963.PubMed
14.
Zurück zum Zitat Gaffney, D. K., et al. (2003). Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. International Journal of Radiation Oncology Biology Physics, 56(4), 922–928. Gaffney, D. K., et al. (2003). Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. International Journal of Radiation Oncology Biology Physics, 56(4), 922–928.
15.
Zurück zum Zitat Kedzia, W., et al. (2002). Immunohistochemical assay of p53, cyclin D1, c-erbB2, EGFr and Ki-67 proteins in HPV-positive and HPV-negative cervical cancers. Folia Histochemica Cytobiologica, 40, 37–41. Kedzia, W., et al. (2002). Immunohistochemical assay of p53, cyclin D1, c-erbB2, EGFr and Ki-67 proteins in HPV-positive and HPV-negative cervical cancers. Folia Histochemica Cytobiologica, 40, 37–41.
16.
Zurück zum Zitat Biesterfeld, S., et al. (1999). Absence of epidermal growth factor receptor expression in squamous cell carcinoma of the uterine cervix is an indicator of limited tumor disease. Oncology Reports, 6, 205–209.PubMed Biesterfeld, S., et al. (1999). Absence of epidermal growth factor receptor expression in squamous cell carcinoma of the uterine cervix is an indicator of limited tumor disease. Oncology Reports, 6, 205–209.PubMed
17.
Zurück zum Zitat Soto-Cruz, I., et al. (2008). The tyrphostin B42 inhibits cell proliferation and HER-2 autophosphorylation in cervical carcinoma cell lines. Cancer Investigation, 26(2), 136–144.PubMed Soto-Cruz, I., et al. (2008). The tyrphostin B42 inhibits cell proliferation and HER-2 autophosphorylation in cervical carcinoma cell lines. Cancer Investigation, 26(2), 136–144.PubMed
18.
Zurück zum Zitat Vaidya, A. P., Parnes, A. D., & Seiden, M. V. (2005). Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies. Current Treatment Options in Oncology, 6(2), 103–114.PubMed Vaidya, A. P., Parnes, A. D., & Seiden, M. V. (2005). Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies. Current Treatment Options in Oncology, 6(2), 103–114.PubMed
19.
Zurück zum Zitat Bellone, S., et al. (2007). Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecologic Oncology, 106(3), 513–520.PubMed Bellone, S., et al. (2007). Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecologic Oncology, 106(3), 513–520.PubMed
20.
Zurück zum Zitat Goncalves, A., et al. (2008). A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecologic Oncology, 108(1), 42–46.PubMed Goncalves, A., et al. (2008). A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecologic Oncology, 108(1), 42–46.PubMed
21.
Zurück zum Zitat Meric, J. B., et al. (2006). Cyclooxygenase-2 as a target for anticancer drug development. Critical Reviews in Oncology/Hematology, 59, 51–64.PubMed Meric, J. B., et al. (2006). Cyclooxygenase-2 as a target for anticancer drug development. Critical Reviews in Oncology/Hematology, 59, 51–64.PubMed
22.
Zurück zum Zitat Ishikawa, H., et al. (2006). Cyclooxygenase-2 impairs treatment effects of radiotherapy for cervical cancer by inhibition of radiation-induced apoptosis. International Journal of Radiation Oncology Biology Physics, 66(5), 1347–1355. Ishikawa, H., et al. (2006). Cyclooxygenase-2 impairs treatment effects of radiotherapy for cervical cancer by inhibition of radiation-induced apoptosis. International Journal of Radiation Oncology Biology Physics, 66(5), 1347–1355.
23.
Zurück zum Zitat Young, J. L., et al. (2008). Cyclooxygenase-2 in cervical neoplasia: a review. Gynecologic Oncology, 109(1), 140–145.PubMed Young, J. L., et al. (2008). Cyclooxygenase-2 in cervical neoplasia: a review. Gynecologic Oncology, 109(1), 140–145.PubMed
24.
Zurück zum Zitat Ferrandina, G., et al. (2002). Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. Journal of Clinical Oncology, 20, 973–981.PubMed Ferrandina, G., et al. (2002). Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. Journal of Clinical Oncology, 20, 973–981.PubMed
25.
Zurück zum Zitat Ferrandina, G., et al. (2002). Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications. British Journal of Cancer, 87, 1145–1152.PubMed Ferrandina, G., et al. (2002). Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications. British Journal of Cancer, 87, 1145–1152.PubMed
26.
Zurück zum Zitat Ferrandina, G., et al. (2003). Cyclooxygenase-2 (COX-2) expression in locally advanced cervical cancer patients undergoing chemoradiation plus surgery. International Journal of Radiation Oncology Biology Physics, 55, 21–27. Ferrandina, G., et al. (2003). Cyclooxygenase-2 (COX-2) expression in locally advanced cervical cancer patients undergoing chemoradiation plus surgery. International Journal of Radiation Oncology Biology Physics, 55, 21–27.
27.
Zurück zum Zitat Chen, H. H., et al. (2005). Increased expression of nitric oxide synthase and cyclooxygenase-2 is associated with poor survival in cervical cancer treated with radiotherapy. International Journal of Radiation Oncology Biology Physics, 63, 1093–1100. Chen, H. H., et al. (2005). Increased expression of nitric oxide synthase and cyclooxygenase-2 is associated with poor survival in cervical cancer treated with radiotherapy. International Journal of Radiation Oncology Biology Physics, 63, 1093–1100.
28.
Zurück zum Zitat Kim, H. J., et al. (2003). High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy. International Journal of Radiation Oncology Biology Physics, 55, 16–20. Kim, H. J., et al. (2003). High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy. International Journal of Radiation Oncology Biology Physics, 55, 16–20.
29.
Zurück zum Zitat Kim, J. Y., et al. (2001). Tumor apoptosis in cervical cancer: its role as a prognostic factor in 42 radiotherapy patients. International Journal of Cancer, 96, 305–312. Kim, J. Y., et al. (2001). Tumor apoptosis in cervical cancer: its role as a prognostic factor in 42 radiotherapy patients. International Journal of Cancer, 96, 305–312.
30.
Zurück zum Zitat Kim, J. Y., et al. (2005). Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. Gynecologic Oncology, 97, 337–341.PubMed Kim, J. Y., et al. (2005). Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. Gynecologic Oncology, 97, 337–341.PubMed
31.
Zurück zum Zitat Distefano, M., et al. (2004). Concomitant radiochemotherapy plus surgery in locally advanced cervical cancer: update of clinical outcome and cyclooxygenase-2 as predictor of treatment susceptibility. Oncology, 67, 103–111.PubMed Distefano, M., et al. (2004). Concomitant radiochemotherapy plus surgery in locally advanced cervical cancer: update of clinical outcome and cyclooxygenase-2 as predictor of treatment susceptibility. Oncology, 67, 103–111.PubMed
32.
Zurück zum Zitat Riou, G., et al. (1987). C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix. Lancet, 1, 761–763.PubMed Riou, G., et al. (1987). C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix. Lancet, 1, 761–763.PubMed
33.
Zurück zum Zitat Riou, G. F., Bourhis, J., & Le, M. G. (1990). The c-myc proto-oncogene in invasive carcinomas of the uterine cervix: clinical relevance of overexpression in early stages of the cancer. Anticancer Research, 10, 1225–1231.PubMed Riou, G. F., Bourhis, J., & Le, M. G. (1990). The c-myc proto-oncogene in invasive carcinomas of the uterine cervix: clinical relevance of overexpression in early stages of the cancer. Anticancer Research, 10, 1225–1231.PubMed
34.
Zurück zum Zitat Bourhis, J., et al. (1990). Prognostic value of c-myc proto-oncogene overexpression in early invasive carcinoma of the cervix. Journal of Clinical Oncology, 8, 1789–1796.PubMed Bourhis, J., et al. (1990). Prognostic value of c-myc proto-oncogene overexpression in early invasive carcinoma of the cervix. Journal of Clinical Oncology, 8, 1789–1796.PubMed
35.
Zurück zum Zitat Riou, G., et al. (1988). Somatic deletions and mutations of c-Ha-ras gene in human cervical cancers. Oncogene, 3, 329–333.PubMed Riou, G., et al. (1988). Somatic deletions and mutations of c-Ha-ras gene in human cervical cancers. Oncogene, 3, 329–333.PubMed
36.
Zurück zum Zitat Baykal, C., et al. (2003). Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas. Gynecologic Oncology, 88, 123–129.PubMed Baykal, C., et al. (2003). Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas. Gynecologic Oncology, 88, 123–129.PubMed
37.
Zurück zum Zitat Markowska, J., et al. (2007). Significance of hypoxia in uterine cervical cancer. Multicentre study. European Journal of Gynaecologic Oncology, 28(5), 386–388. Markowska, J., et al. (2007). Significance of hypoxia in uterine cervical cancer. Multicentre study. European Journal of Gynaecologic Oncology, 28(5), 386–388.
38.
Zurück zum Zitat Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nature Review Cancer, 3, 721–732. Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nature Review Cancer, 3, 721–732.
39.
Zurück zum Zitat Bachtiary, B., et al. (2003). Overexpression of hypoxia-inducible factor 1 α indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clinical Cancer Research, 9, 2234–2240.PubMed Bachtiary, B., et al. (2003). Overexpression of hypoxia-inducible factor 1 α indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clinical Cancer Research, 9, 2234–2240.PubMed
40.
Zurück zum Zitat Birner, P., et al. (2000). Overexpression of hypoxia-inducible factor 1 alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Research, 60, 4693–4696.PubMed Birner, P., et al. (2000). Overexpression of hypoxia-inducible factor 1 alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Research, 60, 4693–4696.PubMed
41.
Zurück zum Zitat Ishikawa, H., et al. (2004). Expression of hypoxic-inducicle factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. International Journal of Radiation Oncology Biology Physics, 60, 513–521. Ishikawa, H., et al. (2004). Expression of hypoxic-inducicle factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. International Journal of Radiation Oncology Biology Physics, 60, 513–521.
42.
Zurück zum Zitat Mayer, A., et al. (2004). Lack of correlation between expression of HIF-1α protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix. Cancer Research, 64, 5876–5881.PubMed Mayer, A., et al. (2004). Lack of correlation between expression of HIF-1α protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix. Cancer Research, 64, 5876–5881.PubMed
43.
Zurück zum Zitat Quintero, M., Mackenzie, N., & Brennan, P. A. (2004). Hypoxia-inducible factor 1 (HIF-1α) in cancer. European Journal of Surgical Oncology, 30, 465–468.PubMed Quintero, M., Mackenzie, N., & Brennan, P. A. (2004). Hypoxia-inducible factor 1 (HIF-1α) in cancer. European Journal of Surgical Oncology, 30, 465–468.PubMed
44.
Zurück zum Zitat Hutchison, G. J., et al. (2004). Hypoxia-inducible factor 1α expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clinical Cancer Research, 10, 8405–8412.PubMed Hutchison, G. J., et al. (2004). Hypoxia-inducible factor 1α expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clinical Cancer Research, 10, 8405–8412.PubMed
45.
Zurück zum Zitat Kawanaka, T., et al. (2008). Prognostic significance of HIF-2alpha expression on tumor infiltrating macrophages in patients with uterine cervical cancer undergoing radiotherapy. Journal of Medical Investigation, 55(1–2), 78–86.PubMed Kawanaka, T., et al. (2008). Prognostic significance of HIF-2alpha expression on tumor infiltrating macrophages in patients with uterine cervical cancer undergoing radiotherapy. Journal of Medical Investigation, 55(1–2), 78–86.PubMed
46.
Zurück zum Zitat Santin, A. D., et al. (1999). Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Obstetrics & Gynecology, 94, 78–82. Santin, A. D., et al. (1999). Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Obstetrics & Gynecology, 94, 78–82.
47.
Zurück zum Zitat Lee, J. S., et al. (2002). Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression. Gynecologic Oncology, 85, 469–475.PubMed Lee, J. S., et al. (2002). Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression. Gynecologic Oncology, 85, 469–475.PubMed
48.
Zurück zum Zitat Soufla, G., et al. (2005). VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. Cancer Letters, 221(1), 105–118.PubMed Soufla, G., et al. (2005). VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. Cancer Letters, 221(1), 105–118.PubMed
49.
Zurück zum Zitat Bachtiary, B., et al. (2002). Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival. Cancer Letters, 179, 197–03.PubMed Bachtiary, B., et al. (2002). Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival. Cancer Letters, 179, 197–03.PubMed
50.
Zurück zum Zitat Cheng, W. F., et al. (2000). Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstetrics & Gynecology, 96, 721–726. Cheng, W. F., et al. (2000). Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstetrics & Gynecology, 96, 721–726.
51.
Zurück zum Zitat Baritaki, S., et al. (2007). Overexpression of VEGF and TGF-beta1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection. International Journal of Oncology, 31(1), 69–79.PubMed Baritaki, S., et al. (2007). Overexpression of VEGF and TGF-beta1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection. International Journal of Oncology, 31(1), 69–79.PubMed
52.
Zurück zum Zitat Lee, I. J., et al. (2002). Prognostic value of vascular endothelial growth factor in stage IB carcinoma of the uterine cervix. International Journal of Radiation Oncology Biology Physics, 54, 768–779. Lee, I. J., et al. (2002). Prognostic value of vascular endothelial growth factor in stage IB carcinoma of the uterine cervix. International Journal of Radiation Oncology Biology Physics, 54, 768–779.
53.
Zurück zum Zitat Loncaster, J. A., et al. (2000). Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. British Journal of Cancer, 83, 620–625.PubMed Loncaster, J. A., et al. (2000). Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. British Journal of Cancer, 83, 620–625.PubMed
54.
Zurück zum Zitat Kang, J. O., & Hong, S. E. (2004). The prognostic effect of VEGF expression in squamous cell carcinoma of the cervix treated with radiation therapy alone. Journal of Korean Medical Science, 19, 693–697.PubMedCrossRef Kang, J. O., & Hong, S. E. (2004). The prognostic effect of VEGF expression in squamous cell carcinoma of the cervix treated with radiation therapy alone. Journal of Korean Medical Science, 19, 693–697.PubMedCrossRef
55.
Zurück zum Zitat Airley, R., et al. (2001). Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clinical Cancer Research, 7(4), 928–934.PubMed Airley, R., et al. (2001). Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clinical Cancer Research, 7(4), 928–934.PubMed
56.
Zurück zum Zitat Lee, W. Y., et al. (2008). Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence. Gynecologic Oncology, 108(2), 377–384.PubMed Lee, W. Y., et al. (2008). Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence. Gynecologic Oncology, 108(2), 377–384.PubMed
57.
Zurück zum Zitat Goh, P. P., Sze, D. M., & Roufogalis, B. D. (2007). Molecular and cellular regulators of cancer angiogenesis. Current Cancer Drug Targets, 7(8), 743–758.PubMed Goh, P. P., Sze, D. M., & Roufogalis, B. D. (2007). Molecular and cellular regulators of cancer angiogenesis. Current Cancer Drug Targets, 7(8), 743–758.PubMed
58.
Zurück zum Zitat Polette, M., et al. (2004). Tumour invasion and matrix metalloproteinases. Critical Reviews in Oncology Hematology, 49, 179–186. Polette, M., et al. (2004). Tumour invasion and matrix metalloproteinases. Critical Reviews in Oncology Hematology, 49, 179–186.
59.
Zurück zum Zitat Raza, S. L., & Cornelius, L. A. (2000). Matrix metalloproteinases: pro- and anti-angiogenic activities. Journal of Investigative Dermatology Symposium Proceeding, 5, 47–54. Raza, S. L., & Cornelius, L. A. (2000). Matrix metalloproteinases: pro- and anti-angiogenic activities. Journal of Investigative Dermatology Symposium Proceeding, 5, 47–54.
60.
Zurück zum Zitat Lizarraga, F., et al. (2005). Tissue inhibitor of metalloproteinases-4 is expressed in cervical cancer patients. Anticancer Research, 25, 623–627.PubMed Lizarraga, F., et al. (2005). Tissue inhibitor of metalloproteinases-4 is expressed in cervical cancer patients. Anticancer Research, 25, 623–627.PubMed
61.
Zurück zum Zitat Zhang, Y., et al. (2008). Adenovirus carrying TIMP-3: a potential tool for cervical cancer treatment. Gynecologic Oncology, 108(1), 234–240.PubMed Zhang, Y., et al. (2008). Adenovirus carrying TIMP-3: a potential tool for cervical cancer treatment. Gynecologic Oncology, 108(1), 234–240.PubMed
62.
Zurück zum Zitat Davidson, B., et al. (1999). MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma—a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecologic Oncology, 73(3), 372–382.PubMed Davidson, B., et al. (1999). MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma—a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecologic Oncology, 73(3), 372–382.PubMed
63.
Zurück zum Zitat Zhai, Y., et al. (2005). Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion. Cancer Research, 65(15), 6543–6550.PubMed Zhai, Y., et al. (2005). Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion. Cancer Research, 65(15), 6543–6550.PubMed
64.
Zurück zum Zitat Yaldizl, M., et al. (2005). Expression of E-cadherin in squamous cell carcinomas of the cervix with correlations to clinicopathological features. European Journal of Gynaecologic Oncology, 26, 95–98. Yaldizl, M., et al. (2005). Expression of E-cadherin in squamous cell carcinomas of the cervix with correlations to clinicopathological features. European Journal of Gynaecologic Oncology, 26, 95–98.
65.
Zurück zum Zitat Kaplanis, K., et al. (2005). E-cadherin expression during progression of squamous intraepithelial lesions in the uterine cervix. European Journal of Gynaecologic Oncology, 26(6), 608–610. Kaplanis, K., et al. (2005). E-cadherin expression during progression of squamous intraepithelial lesions in the uterine cervix. European Journal of Gynaecologic Oncology, 26(6), 608–610.
66.
Zurück zum Zitat Van Aarsen, L. A., et al. (2008). Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Research, 68(2), 561–570.PubMed Van Aarsen, L. A., et al. (2008). Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Research, 68(2), 561–570.PubMed
67.
Zurück zum Zitat Hazelbag, S., et al. (2007). Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. Journal of Pathology, 212(3), 316–324.PubMed Hazelbag, S., et al. (2007). Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. Journal of Pathology, 212(3), 316–324.PubMed
68.
Zurück zum Zitat Hazelbag, S., et al. (2004). Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer. International Journal of Cancer, 112, 1020–1028. Hazelbag, S., et al. (2004). Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer. International Journal of Cancer, 112, 1020–1028.
69.
Zurück zum Zitat Bouda, J., et al. (2005). CD44v6 as a prognostic factor in cervical carcinoma FIGO stage IB. Anticancer Research, 25, 617–622.PubMed Bouda, J., et al. (2005). CD44v6 as a prognostic factor in cervical carcinoma FIGO stage IB. Anticancer Research, 25, 617–622.PubMed
70.
Zurück zum Zitat Speiser, P., et al. (1997). CD44 is an independent prognostic factor in early-stage cervical cancer. International Journal of Cancer, 74(2), 185–188. Speiser, P., et al. (1997). CD44 is an independent prognostic factor in early-stage cervical cancer. International Journal of Cancer, 74(2), 185–188.
71.
Zurück zum Zitat Costa, S., et al. (2001). CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma. Gynecologic Oncology, 80, 67–73.PubMed Costa, S., et al. (2001). CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma. Gynecologic Oncology, 80, 67–73.PubMed
72.
Zurück zum Zitat Beskow, C., et al. (2006). Expression of DNA damage response proteins and complete remission after radiotherapy of stage IB-IIA of cervical cancer. British Journal of Cancer, 94(11), 1683–1689.PubMed Beskow, C., et al. (2006). Expression of DNA damage response proteins and complete remission after radiotherapy of stage IB-IIA of cervical cancer. British Journal of Cancer, 94(11), 1683–1689.PubMed
73.
Zurück zum Zitat Lee, J. M., & Bernstein, A. (1995). Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Reviews, 14(2), 149–161.PubMed Lee, J. M., & Bernstein, A. (1995). Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Reviews, 14(2), 149–161.PubMed
74.
Zurück zum Zitat Cuddihy, A. R., & Bristow, R. G. (2004). The p53 protein family and radiation sensitivity: Yes or no? Cancer Metastasis Reviews, 23(3–4), 237–257.PubMed Cuddihy, A. R., & Bristow, R. G. (2004). The p53 protein family and radiation sensitivity: Yes or no? Cancer Metastasis Reviews, 23(3–4), 237–257.PubMed
75.
Zurück zum Zitat Alfsen, G. C., et al. (2003). The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinomas of the uterine cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with international federation of gynecology and obstetrics stage I and II adenocarcinoma. Cancer, 98(9), 1880–1889.PubMed Alfsen, G. C., et al. (2003). The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinomas of the uterine cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with international federation of gynecology and obstetrics stage I and II adenocarcinoma. Cancer, 98(9), 1880–1889.PubMed
76.
Zurück zum Zitat Wootipoom, V., et al. (2004). Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy. Gynecologic Oncology, 94(3), 636–642.PubMed Wootipoom, V., et al. (2004). Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy. Gynecologic Oncology, 94(3), 636–642.PubMed
77.
Zurück zum Zitat Zhou, J. H., et al. (2006). Fas-mediated pathway and apoptosis in normal cervix, cervical intraepithelial neoplasia and cervical squamous cancer. Oncology Reports, 16(2), 307–311.PubMed Zhou, J. H., et al. (2006). Fas-mediated pathway and apoptosis in normal cervix, cervical intraepithelial neoplasia and cervical squamous cancer. Oncology Reports, 16(2), 307–311.PubMed
78.
Zurück zum Zitat Knox, P. G., et al. (2003). Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand. Journal of Immunology, 170(2), 677–685. Knox, P. G., et al. (2003). Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand. Journal of Immunology, 170(2), 677–685.
79.
Zurück zum Zitat Mora, N., Rosales, R., & Rosales, C. (2007). R-Ras promotes metastasis of cervical cancer epithelial cells. Cancer Immunology, Immunotherapy, 56(4), 535–544.PubMed Mora, N., Rosales, R., & Rosales, C. (2007). R-Ras promotes metastasis of cervical cancer epithelial cells. Cancer Immunology, Immunotherapy, 56(4), 535–544.PubMed
80.
Zurück zum Zitat Rincón-Arano, H., et al. (2003). R-Ras promotes tumor growth of cervical epithelial cells. Cancer, 97(3), 575–585.PubMed Rincón-Arano, H., et al. (2003). R-Ras promotes tumor growth of cervical epithelial cells. Cancer, 97(3), 575–585.PubMed
81.
Zurück zum Zitat Rotblat, B., et al. (2008). The ras inhibitor farnesylthiosalicylic Acid (salirasib) disrupts the spatiotemporal localization of active ras: a potential treatment for cancer. Methods in Enzymology, 439, 467–489.PubMed Rotblat, B., et al. (2008). The ras inhibitor farnesylthiosalicylic Acid (salirasib) disrupts the spatiotemporal localization of active ras: a potential treatment for cancer. Methods in Enzymology, 439, 467–489.PubMed
82.
Zurück zum Zitat Oka, K., Suzuki, Y., & Nakano, T. (2000). Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone: radiotherapeutic effect and prognosis. Cancer, 88(12), 2766–2773.PubMed Oka, K., Suzuki, Y., & Nakano, T. (2000). Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone: radiotherapeutic effect and prognosis. Cancer, 88(12), 2766–2773.PubMed
83.
Zurück zum Zitat Suzuki, Y., et al. (2004). Immunohistochemical study of cell cycle-associated proteins in adenocarcinoma of the uterine cervix treated with radiotherapy alone: p53 status has a strong impact on prognosis. International Journal of Radiation Oncology Biology Physics, 60, 231–236. Suzuki, Y., et al. (2004). Immunohistochemical study of cell cycle-associated proteins in adenocarcinoma of the uterine cervix treated with radiotherapy alone: p53 status has a strong impact on prognosis. International Journal of Radiation Oncology Biology Physics, 60, 231–236.
84.
Zurück zum Zitat Kim, J. Y., et al. (2007). Clinical significance of p27 and Skp2 protein expression in uterine cervical neoplasm. International Journal of Gynecological Pathology, 26(3), 242–247.PubMed Kim, J. Y., et al. (2007). Clinical significance of p27 and Skp2 protein expression in uterine cervical neoplasm. International Journal of Gynecological Pathology, 26(3), 242–247.PubMed
85.
Zurück zum Zitat Wakatsuki, M., et al. (2008). p73 Protein Expression Correlates With Radiation-Induced Apoptosis in the Lack of p53 Response to Radiation Therapy for Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 70(4), 1189–1194. Wakatsuki, M., et al. (2008). p73 Protein Expression Correlates With Radiation-Induced Apoptosis in the Lack of p53 Response to Radiation Therapy for Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 70(4), 1189–1194.
86.
Zurück zum Zitat Santucci, M. A., et al. (2000). Radiation-induced gadd45 expression correlates with clinical response to radiotherapy of cervical carcinoma. International Journal of Radiation Oncology Biology Physics, 46(2), 411–416. Santucci, M. A., et al. (2000). Radiation-induced gadd45 expression correlates with clinical response to radiotherapy of cervical carcinoma. International Journal of Radiation Oncology Biology Physics, 46(2), 411–416.
87.
Zurück zum Zitat Cerciello, F., et al. (2005). G2/M cell cycle checkpoint is functional in cervical cancer patients after initiation of external beam radiotherapy. International Journal of Radiation Oncology Biology Physics, 62(5), 1390–1398. Cerciello, F., et al. (2005). G2/M cell cycle checkpoint is functional in cervical cancer patients after initiation of external beam radiotherapy. International Journal of Radiation Oncology Biology Physics, 62(5), 1390–1398.
88.
Zurück zum Zitat Lee, J. S., et al. (2006). Expression of PTEN in the progression of cervical neoplasia and its relation to tumor behavior and angiogenesis in invasive squamous cell carcinoma. Journal of Surgical Oncology, 93, 233–240.PubMed Lee, J. S., et al. (2006). Expression of PTEN in the progression of cervical neoplasia and its relation to tumor behavior and angiogenesis in invasive squamous cell carcinoma. Journal of Surgical Oncology, 93, 233–240.PubMed
89.
Zurück zum Zitat Cheung, T. H., et al. (2004). Epigenetic and genetic alternation of PTEN in cervical neoplasm. Gynecologic Oncology, 93(3), 621–627.PubMed Cheung, T. H., et al. (2004). Epigenetic and genetic alternation of PTEN in cervical neoplasm. Gynecologic Oncology, 93(3), 621–627.PubMed
90.
Zurück zum Zitat Nair, A., et al. (2003). NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene, 22(1), 50–58.PubMed Nair, A., et al. (2003). NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene, 22(1), 50–58.PubMed
91.
Zurück zum Zitat Han, S., et al. (2008). PPAR{beta}/{delta}agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3-K and NF-{kappa}B signals. American Journal of Physiology- Lung Cell and Molecular Physiology, 294, L1238–L1249. Han, S., et al. (2008). PPAR{beta}/{delta}agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3-K and NF-{kappa}B signals. American Journal of Physiology- Lung Cell and Molecular Physiology, 294, L1238–L1249.
92.
Zurück zum Zitat Köster, F., et al. (2007). Correlation of DNA mismatch repair protein hMSH2 immunohistochemistry with p53 and apoptosis in cervical carcinoma. Anticancer Research, 27(1A), 63–68.PubMed Köster, F., et al. (2007). Correlation of DNA mismatch repair protein hMSH2 immunohistochemistry with p53 and apoptosis in cervical carcinoma. Anticancer Research, 27(1A), 63–68.PubMed
93.
Zurück zum Zitat Wilson, C. R., et al. (2000). Expression of Ku70 correlates with survival in carcinoma of the cervix. British Journal of Cancer, 83(12), 1702–1706.PubMed Wilson, C. R., et al. (2000). Expression of Ku70 correlates with survival in carcinoma of the cervix. British Journal of Cancer, 83(12), 1702–1706.PubMed
94.
Zurück zum Zitat Ayene, I. S., Ford, L. P., & Koch, C. J. (2005). Ku protein targeting by Ku70 small interfering RNA enhances human cancer cell response to topoisomerase II inhibitor and gamma radiation. Molecular Cancer Therapeutics, 4(4), 529–536.PubMed Ayene, I. S., Ford, L. P., & Koch, C. J. (2005). Ku protein targeting by Ku70 small interfering RNA enhances human cancer cell response to topoisomerase II inhibitor and gamma radiation. Molecular Cancer Therapeutics, 4(4), 529–536.PubMed
95.
Zurück zum Zitat Harima, Y., et al. (2003). Expression of Ku80 in cervical cancer correlates with response to radiotherapy and survival. American Journal of Clinical Oncology, 26(4), 80–85. Harima, Y., et al. (2003). Expression of Ku80 in cervical cancer correlates with response to radiotherapy and survival. American Journal of Clinical Oncology, 26(4), 80–85.
96.
Zurück zum Zitat Ishikawa, M., et al. (2006). Overexpression of p16 INK4a as an indicator for human papillomavirus oncogenic activity in cervical squamous neoplasia. International Journal of Gynecological Cancer, 16(1), 347–353.PubMed Ishikawa, M., et al. (2006). Overexpression of p16 INK4a as an indicator for human papillomavirus oncogenic activity in cervical squamous neoplasia. International Journal of Gynecological Cancer, 16(1), 347–353.PubMed
97.
Zurück zum Zitat Martin, C. M., et al. (2007). Gene discovery in cervical cancer: towards diagnostic and therapeutic biomarkers. Molecular Diagnosis & Therapies, 11(5), 277–290. Martin, C. M., et al. (2007). Gene discovery in cervical cancer: towards diagnostic and therapeutic biomarkers. Molecular Diagnosis & Therapies, 11(5), 277–290.
98.
Zurück zum Zitat Madrigal, M., et al. (1997). In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma. Gynecological Oncology, 64(1), 18–25. Madrigal, M., et al. (1997). In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma. Gynecological Oncology, 64(1), 18–25.
99.
Zurück zum Zitat Sima, N., et al. (2007). Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Gynecological Oncology, 106(2), 299–304. Sima, N., et al. (2007). Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Gynecological Oncology, 106(2), 299–304.
100.
Zurück zum Zitat Tan, T. M., & Ting, R. C. (1995). In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Research, 55(20), 4599–4605.PubMed Tan, T. M., & Ting, R. C. (1995). In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Research, 55(20), 4599–4605.PubMed
101.
Zurück zum Zitat de Wilde, J., et al. (2008). Gene expression profiling to identify markers associated with deregulated hTERT in HPV-transformed keratinocytes and cervical cancer. International Journal of Cancer, 122(4), 877–888. de Wilde, J., et al. (2008). Gene expression profiling to identify markers associated with deregulated hTERT in HPV-transformed keratinocytes and cervical cancer. International Journal of Cancer, 122(4), 877–888.
102.
Zurück zum Zitat Amine, A., et al. (2006). Cidofovir administered with radiation displays an antiangiogenic effect mediated by E6 inhibition and subsequent TP53-dependent VEGF repression in HPV18+ cell lines. Radiation Research, 166(4), 600–610.PubMed Amine, A., et al. (2006). Cidofovir administered with radiation displays an antiangiogenic effect mediated by E6 inhibition and subsequent TP53-dependent VEGF repression in HPV18+ cell lines. Radiation Research, 166(4), 600–610.PubMed
103.
Zurück zum Zitat Abdulkarim, B., et al. (2002). Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene, 21(15), 2334–2346.PubMed Abdulkarim, B., et al. (2002). Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene, 21(15), 2334–2346.PubMed
104.
Zurück zum Zitat Harima, Y., et al. (1999). Genetic alterations on chromosome 17p associated with response to radiotherapy in bulky cervical cancer. British Journal of Cancer, 81(1), 108–113.PubMed Harima, Y., et al. (1999). Genetic alterations on chromosome 17p associated with response to radiotherapy in bulky cervical cancer. British Journal of Cancer, 81(1), 108–113.PubMed
105.
Zurück zum Zitat Harima, Y., et al. (2000). Loss of heterozygosity on chromosome 6p21.2 as a potential marker for recurrence after radiotherapy of human cervical cancer. Clinical Cancer Research, 6(3), 1079–1085.PubMed Harima, Y., et al. (2000). Loss of heterozygosity on chromosome 6p21.2 as a potential marker for recurrence after radiotherapy of human cervical cancer. Clinical Cancer Research, 6(3), 1079–1085.PubMed
106.
Zurück zum Zitat Kozlowski, L., et al. (2006). Loss of heterozygosity on chromosomes 2p, 3p, 18q21.3 and 11p15.5 as a poor prognostic factor in stage II and III (FIGO) cervical cancer treated by radiotherapy. Neoplasma, 53(5), 440–443.PubMed Kozlowski, L., et al. (2006). Loss of heterozygosity on chromosomes 2p, 3p, 18q21.3 and 11p15.5 as a poor prognostic factor in stage II and III (FIGO) cervical cancer treated by radiotherapy. Neoplasma, 53(5), 440–443.PubMed
107.
Zurück zum Zitat Rao, P. H., et al. (2004). Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BioMed Central Cancer, 4, 5.PubMed Rao, P. H., et al. (2004). Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BioMed Central Cancer, 4, 5.PubMed
108.
Zurück zum Zitat Terra, A. P., et al. (2007). Aberrant promoter methylation can be useful as a marker of recurrent disease in patients with cervical intraepithelial neoplasia grade III. Tumori, 93(6), 572–579.PubMed Terra, A. P., et al. (2007). Aberrant promoter methylation can be useful as a marker of recurrent disease in patients with cervical intraepithelial neoplasia grade III. Tumori, 93(6), 572–579.PubMed
109.
Zurück zum Zitat Lindström, A. K., et al. (2007). Predicting the outcome of squamous cell carcinoma of the uterine cervix using combinations of individual tumor marker expressions. Anticancer Research, 27(3B), 1609–1615.PubMed Lindström, A. K., et al. (2007). Predicting the outcome of squamous cell carcinoma of the uterine cervix using combinations of individual tumor marker expressions. Anticancer Research, 27(3B), 1609–1615.PubMed
110.
Zurück zum Zitat Narayan, G., et al. (2007). Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer, 46(4), 373–384.PubMed Narayan, G., et al. (2007). Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer, 46(4), 373–384.PubMed
111.
Zurück zum Zitat Achary, M. P., et al. (2000). Cell lines from the same cervical carcinoma but with different radiosensitivities exhibit different cDNA microarray patterns of gene expression. Cytogenetics and Cell Genetics, 91(1–4), 39–43.PubMed Achary, M. P., et al. (2000). Cell lines from the same cervical carcinoma but with different radiosensitivities exhibit different cDNA microarray patterns of gene expression. Cytogenetics and Cell Genetics, 91(1–4), 39–43.PubMed
112.
Zurück zum Zitat Chao, A., et al. (2006). Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. International Journal of Cancer, 119(1), 91–98. Chao, A., et al. (2006). Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. International Journal of Cancer, 119(1), 91–98.
113.
Zurück zum Zitat Chen, Y., et al. (2003). Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Research, 63(8), 1927–1935.PubMed Chen, Y., et al. (2003). Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Research, 63(8), 1927–1935.PubMed
114.
Zurück zum Zitat Gaffney, D. K., et al. (2005). Feasibility of RNA collection for micro-array gene expression analysis in the treatment of cervical carcinoma: a scientific correlate of RTOG C-0128. Gynecological Oncology, 97(2), 607–611. Gaffney, D. K., et al. (2005). Feasibility of RNA collection for micro-array gene expression analysis in the treatment of cervical carcinoma: a scientific correlate of RTOG C-0128. Gynecological Oncology, 97(2), 607–611.
115.
Zurück zum Zitat Collis, S. J., & De Weese, T. L. (2004). Enhanced radiation response through directed molecular targeting approaches. Cancer Metastasis Reviews, 23(3–4), 277–292.PubMed Collis, S. J., & De Weese, T. L. (2004). Enhanced radiation response through directed molecular targeting approaches. Cancer Metastasis Reviews, 23(3–4), 277–292.PubMed
116.
Zurück zum Zitat Gu, W., et al. (2006). Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Therapy, 13(11), 1023–1032.PubMed Gu, W., et al. (2006). Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Therapy, 13(11), 1023–1032.PubMed
117.
Zurück zum Zitat Moeller, B. J., Richardson, R. A., & Dewhirst, M. W. (2007). Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Reviews, 26(2), 241–248.PubMed Moeller, B. J., Richardson, R. A., & Dewhirst, M. W. (2007). Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Reviews, 26(2), 241–248.PubMed
Metadaten
Titel
Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents
verfasst von
Nicolas Magné
Cyrus Chargari
Eric Deutsch
Pierre Castadot
Mitra Ghalibafian
Jean Bourhis
Christine Haie-Meder
Publikationsdatum
01.12.2008
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 4/2008
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-008-9162-7

Weitere Artikel der Ausgabe 4/2008

Cancer and Metastasis Reviews 4/2008 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.